Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-21 |
{
"resourceType" : "Citation",
"id" : "267247",
"meta" : {
"versionId" : "1",
"lastUpdated" : "2024-08-01T12:37:46.381Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Citation 267247</b></p><a name=\"267247\"> </a><a name=\"hc267247\"> </a><a name=\"267247-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 1; Last updated: 2024-08-01 12:37:46+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-journal-article-citation.html\">JournalArticleCitation</a></p></div><p><b>url</b>: <a href=\"Citation-267247.html\">Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</a></p><p><b>identifier</b>: FEvIR Object Identifier/267247, <code>https://pubmed.ncbi.nlm.nih.gov</code>/15832493, <a href=\"http://terminology.hl7.org/6.1.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.47</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-21 14:09:14+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use\">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}\">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title=\"Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}\">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>approvalDate</b>: 2005-05-18</p><p><b>lastReviewDate</b>: 2019-11-09</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type citation-source}\">Citation Source</span></p><p><b>classifier</b>: <span title=\"Codes:\">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}\">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}\">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type medline-medline}\">Medline Citation Status of Medline</span>, <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-ppublish}\">PubMed PublicationStatus of ppublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}\">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2005-04-19 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}\">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2005-05-19 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}\">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2005-04-19 09:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15832493, <code>https://doi.org</code>/10.2165/00024677-200201060-00006</p><h3>Titles</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/title-type primary}\">Primary title</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></td><td><div><p>Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</p>\n</div></td></tr></table><h3>Abstracts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p><AbstractText Label="UNLABELLED">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of < or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (< or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.\n<strong>CONCLUSIONS:</strong> Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.</p>\n</div></td></tr></table><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/published-in-type D020492}\">Periodical</span></p><p><b>identifier</b>: Print ISSN Type/1175-6349, ISOAbbreviation/Treat Endocrinol, ISSN Linking/1175-6349, Medline Title Abbreviation/Treat Endocrinol, NLM Unique ID/101132977</p><p><b>title</b>: Treatments in endocrinology</p><p><b>publisherLocation</b>: New Zealand</p></blockquote><p><b>citedMedium</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-medium print}\">Print</span></p><p><b>volume</b>: 1</p><p><b>issue</b>: 6</p><p><b>articleDate</b>: 2002</p><p><b>publicationDateText</b>: 2002</p><p><b>language</b>: <span title=\"Codes:{urn:ietf:bcp:47 en}\">English</span></p><p><b>pageString</b>: 411-4</p></blockquote><h3>WebLocations</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Classifier</b></td><td><b>Url</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}\">Abstract</span></td><td><a href=\"https://pubmed.ncbi.nlm.nih.gov/15832493/\">https://pubmed.ncbi.nlm.nih.gov/15832493/</a></td></tr></table><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}\">Publishing Model</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier Print}\">Print</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}\">Chemical</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D007004}\">Hypoglycemic Agents</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D045162}\">Thiazolidinediones</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 05V02F2KDG}, {https://meshb.nlm.nih.gov/ D000077154}\">Rosiglitazone</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href=\"#hc267247/meshHeading0\">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}\">Publication type</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016428}\">Journal Article</span>, <span title=\"Codes:{https://meshb.nlm.nih.gov/ D016454}\">Review</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}\">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}\">Citation subset</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}\">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc267247/contributor0\">Wagstaff AJ</a></p><p><b>forenameInitials</b>: AJ</p><p><b>affiliation</b>: Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc267247/contributor1\">Goa KL</a></p><p><b>forenameInitials</b>: KL</p></blockquote></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor0</b></p><a name=\"267247/contributor0\"> </a><a name=\"hc267247/contributor0\"> </a><a name=\"267247/contributor0-en-US\"> </a><p><b>name</b>: Antona J Wagstaff </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor1</b></p><a name=\"267247/contributor1\"> </a><a name=\"hc267247/contributor1\"> </a><a name=\"267247/contributor1-en-US\"> </a><p><b>name</b>: Karen L Goa </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name=\"267247/meshHeading0\"> </a><a name=\"hc267247/meshHeading0\"> </a><a name=\"267247/meshHeading0-en-US\"> </a><p><b>artifact</b>: <a href=\"#hc267247\">Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D003924}\">Diabetes Mellitus, Type 2</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000188}\">drug therapy</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D006801}\">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D007004}\">Hypoglycemic Agents</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D000077154}\">Rosiglitazone</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ D045162}\">Thiazolidinediones</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://meshb.nlm.nih.gov/ Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}\">Yes</span></td></tr></table></blockquote></blockquote></blockquote></div>"
},
"contained" : [
{
"resourceType" : "Practitioner",
"id" : "contributor0",
"name" : [
{
"family" : "Wagstaff",
"given" : [
"Antona J"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor1",
"name" : [
{
"family" : "Goa",
"given" : [
"Karen L"
]
}
]
},
{
"resourceType" : "ArtifactAssessment",
"id" : "meshHeading0",
"artifactReference" : {
"reference" : "#",
"type" : "Citation"
},
"content" : [
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D003924",
"display" : "Diabetes Mellitus, Type 2",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000188",
"display" : "drug therapy"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D006801",
"display" : "Humans",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D007004",
"display" : "Hypoglycemic Agents",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000077154",
"display" : "Rosiglitazone",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"informationType" : "classifier",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D045162",
"display" : "Thiazolidinediones",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://ncithesaurus.nci.nih.gov/ncitbrowser",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
}
]
}
],
"url" : "https://fevir.net/resources/Citation/267247",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "267247",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15832493"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.15.47"
}
],
"version" : "2.0.0-ballot",
"title" : "15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.",
"status" : "active",
"date" : "2024-11-21T14:09:14+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext" : [
{
"code" : {
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "fevir-platform-use",
"display" : "FEvIR Platform Use"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "medline-base",
"display" : "Medline Base",
"userSelected" : false
}
]
}
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate" : "2005-05-18",
"lastReviewDate" : "2019-11-09",
"author" : [
{
"name" : "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "citation-source",
"display" : "Citation Source"
}
]
},
"classifier" : [
{
"text" : "MEDLINE"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-classification-type",
"code" : "medline-owner",
"display" : "MEDLINE Citation Owner"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code" : "NLM",
"display" : "National Library of Medicine, Index Section",
"userSelected" : false
}
]
}
]
}
],
"currentState" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "medline-medline",
"display" : "Medline Citation Status of Medline"
}
]
},
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-publication-status-ppublish",
"display" : "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate" : [
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pubmed",
"display" : "PubMed Pubstatus of Pubmed"
}
]
},
"period" : {
"end" : "2005-04-19T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-medline",
"display" : "PubMed Pubstatus of Medline"
}
]
},
"period" : {
"end" : "2005-05-19T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-entrez",
"display" : "PubMed Pubstatus of Entrez"
}
]
},
"period" : {
"end" : "2005-04-19T09:00:00.000Z"
}
}
],
"citedArtifact" : {
"identifier" : [
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15832493"
},
{
"system" : "https://doi.org",
"value" : "10.2165/00024677-200201060-00006"
}
],
"title" : [
{
"type" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/title-type",
"code" : "primary",
"display" : "Primary title"
}
]
}
],
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
},
"text" : "Spotlight on rosiglitazone in the management of type 2 diabetes mellitus."
}
],
"abstract" : [
{
"text" : "<AbstractText Label=\"UNLABELLED\">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of < or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (< or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.\n**CONCLUSIONS:** Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus."
}
],
"publicationForm" : [
{
"publishedIn" : {
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/published-in-type",
"code" : "D020492",
"display" : "Periodical"
}
]
},
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code" : "Print",
"display" : "Print"
}
],
"text" : "Print ISSN Type"
},
"system" : "https://portal.issn.org",
"value" : "1175-6349"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISOAbbreviation"
},
"system" : "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value" : "Treat Endocrinol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISSN Linking"
},
"system" : "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value" : "1175-6349"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "Medline Title Abbreviation"
},
"system" : "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value" : "Treat Endocrinol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "NLM Unique ID"
},
"system" : "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value" : "101132977"
}
],
"title" : "Treatments in endocrinology",
"publisherLocation" : "New Zealand"
},
"citedMedium" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-medium",
"code" : "print",
"display" : "Print"
}
]
},
"volume" : "1",
"issue" : "6",
"articleDate" : "2002",
"publicationDateText" : "2002",
"language" : [
{
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "English"
}
]
}
],
"pageString" : "411-4"
}
],
"webLocation" : [
{
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/artifact-url-classifier",
"code" : "abstract",
"display" : "Abstract"
}
]
}
],
"url" : "https://pubmed.ncbi.nlm.nih.gov/15832493/"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publishing-model",
"display" : "Publishing Model",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "Print",
"display" : "Print",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "chemical",
"display" : "Chemical",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D007004",
"display" : "Hypoglycemic Agents",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D045162",
"display" : "Thiazolidinediones",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "05V02F2KDG",
"userSelected" : false
},
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D000077154",
"display" : "Rosiglitazone",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
]
},
"artifactAssessment" : [
{
"reference" : "#meshHeading0",
"type" : "ArtifactAssessment"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "publication-type",
"display" : "Publication type"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://meshb.nlm.nih.gov/",
"code" : "D016454",
"display" : "Review",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "knowledge-artifact-type",
"display" : "Knowledge Artifact Type",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
}
],
"artifactAssessment" : [
{
"display" : "Classifier added by Computable Publishing LLC"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/cited-artifact-classification-type",
"code" : "citation-subset",
"display" : "Citation subset",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code" : "IM",
"display" : "IM",
"userSelected" : false
}
]
}
]
}
],
"contributorship" : {
"complete" : true,
"entry" : [
{
"contributor" : {
"reference" : "#contributor0",
"type" : "Practitioner",
"display" : "Wagstaff AJ"
},
"forenameInitials" : "AJ",
"affiliation" : [
{
"display" : "Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com"
}
]
},
{
"contributor" : {
"reference" : "#contributor1",
"type" : "Practitioner",
"display" : "Goa KL"
},
"forenameInitials" : "KL"
}
]
}
}
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change